Volume 59, Issue 1 pp. 25-31
Full Access

Hypervariable region diversity of hepatitis C virus and humoral response: Comparison between patients with or without cirrhosis

Jean-Pierre Allain

Corresponding Author

Jean-Pierre Allain

Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge, United Kingdom

Division of Transfusion Medicine, East Anglian Blood Centre, Long Road, Cambridge CB2 2PT, United Kingdom===Search for more papers by this author
Wenwu Zhai

Wenwu Zhai

Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge, United Kingdom

Search for more papers by this author
Dazhuang Shang

Dazhuang Shang

Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge, United Kingdom

Search for more papers by this author
Erik Timmers

Erik Timmers

Department of Haematology, Division of Transfusion Medicine, University of Cambridge, Cambridge, United Kingdom

Search for more papers by this author
Graeme JM Alexander

Corresponding Author

Graeme JM Alexander

Department of Medicine, Liver Unit, University of Cambridge, Cambridge, United Kingdom

Division of Transfusion Medicine, East Anglian Blood Centre, Long Road, Cambridge CB2 2PT, United Kingdom===Search for more papers by this author

Abstract

To investigate the potential clinical utility of antibody response to HVR1 of HCV, the genomic and amino acid diversity of HVR1 was compared between two groups of four chronic HCV carriers with or without liver cirrhosis. Peptides corresponding to the deduced COOH- and NH2-terminal amino acid sequences of HVR1 were synthesised to assess the reactivity of patient sera to autologous and homologous HVR1 epitopes by enzyme-linked immunosorbent assay. HCV chronic carriers had significantly more frequent cross-reactivity with homologous C- than N-terminal HVR1 peptides. Twelve cirrhotic and eleven noncirrhotic patients had a similar frequency of cross-reactivity with either C- or N-terminal HVR1 peptides. However, noncirrhotic patients had a significantly higher level of C-terminal HVR1 antibody cross-reactivity than cirrhotic patients. In HCV chronic carriers, the magnitude of the immune response to but not the frequency of cross-reactivity with C-terminus HVR1 peptides differ between patients with and without liver cirrhosis. J. Med. Virol. 59:25–31, 1999. © 1999 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.